摘要
目的探讨利培酮口服液联合度洛西汀治疗慢性精神分裂症阴性症状的临床疗效及安全性。方法将172例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮口服液联合度洛西汀治疗)和对照组(单用利培酮口服液治疗),疗程12周,采用阳性和阴性综合征量表(PANSS)和治疗中需处理的不良反应症状量表(TESS)评定疗效和安全性。结果治疗后两组PANSS评分均较治疗前有显著降低(P<0.05)。治疗后第4、8、12周末,研究组PANSS评分显著低于对照组(P<0.05或P<0.01)。两组不良反应均为轻至中度,两组比较无显著性差异。结论利培酮口服液联合度洛西汀较单用利培酮口服液治疗慢性精神分裂症阴性症状具有起效快、疗效好、依从性好的特点。
Objective To evaluate clinical efficacy and safety of risperidone oral solution combined with duloxetme in the treatment of negative symptoms in patients with chronic schizophrenia. Methods 172 chronic schizophrenic patients with predominant negative symptoms were randomly divided into study group treated with risperidone oral solution combined with duloxetine and control group treated with risperidone oral solution monotherapy for 12 weeks. Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Symptom Scale （TESS） were used to assess the efficacy and safety respectively. Results Scores of PANSS at the end of the treatment in both groups decreased significantly compared with the baseline （P 〈 0.05）. At the end of the 4th, 8th, 12th week of the treatment, scores of PANSS in study group were significantly lower than those in control group （P 〈0.05, or P 〈0.01 ）. Side effects in both groups were mild to moderate and there was no significant difference in side effects between the two groups. Conclusion Risperidone oral solution combined with duloxetine has rapid response, good efficacy and good compliance in the treatment of negative symptoms in patients with chronic schizophrenia.
出处
《精神医学杂志》
2013年第3期189-191,共3页
Journal of Psychiatry
